Management of a patient with ventricular bigeminy with mitral valve prolapse during emergency cesarean section
Anaesthesia, Pain & Intensive Care · 2026-06-23 · 30 (5) · 659-662
DOI: 10.35975/apic.v30i5.3246 ↗Abstract
We present the anaesthetic care of a 19-year-old primigravida in 39 weeks and 3 days of pregnancy for emergency Lower Segment Caesarean Section (LSCS) because of non-reassuring fetal heart rate and fetal distress. The patient had mitral valve prolapse with moderate mitral and tricuspid regurgitation and mild pulmonary arterial hypertension with preserved left ventricular function. A preoperative electrocardiograph showed sinus tachycardia with ventricular bigeminy, but the patient was asymptomatic and hemodynamically stable. Due to the underlying cardiac pathology and urgent obstetric intervention, general anaesthesia with invasive monitoring was decided following a multidisciplinary discussion. During surgery ventricular bigeminy was there which was immediately identified and treated by the anaesthesia team with close monitoring, elimination of potential triggers, and intravenous lignocaine. The arrhythmia resolved without progression or hemodynamic deterioration. The caesarean section was uneventful, and the patient was extubated awake, stable, and admitted to the post-anaesthesia care unit for close monitoring. Recovery was uneventful postoperatively, with adequate pain control and no subsequent arrhythmic activity. This case emphasises the value of close intraoperative monitoring and early intervention in arrhythmias in pregnant women with valvular heart disease presenting with an emergency. Keywords: Emergency Lower Segment Caesarean Section, mitral valve prolapse, moderate mitral and tricuspid regurgitation, ventricular bigeminy Citation: Phad U, Mainaparambil IS, Srinivasan NK, Sharma R, Kadam SR. Management of a patient with ventricular bigeminy with mitral valve prolapse during emergency cesarean section. Anaesth. pain intensive care. 2026;30(5):659-662. DOI: 10.35975/apic.v30i5.3246 Received: February 23, 2026; Revised: May 06, 2026; Accepted: May 08, 2026
EUVIMED